Nomura Instinet analyst Christopher Marai says the rolling submission of a new drug application for givosiran that Alnylam Pharmaceuticals announced yesterday pushes back his expected approval timing of mid-2019.The failure to proceed with accelerated approval based on alpha-lipoic acid lowering as a surrogate means that success depends on decreases in annualized attack rates, a much more variable endpoint, Marai tells investors in a research note. He believes the rolling submission is riskier than Alnylam's prior plans and keeps a Reduce rating on the shares with a $73 price target.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).